FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045681719> ?p ?o ?g. }

• W3045681719 endingPage "e001227" @default.
• W3045681719 startingPage "e001227" @default.
• W3045681719 abstract "Objectives Several therapies are used for the treatment of rareautoinflammatory conditions like cryopyrin-associated periodic fever syndromes (CAPS), hyperimmunoglobulin Dsyndrome (HIDS)/mevalonate kinase deficiency (MKD) and tumour necrosis factor receptor-associated periodic syndrome (TRAPS). However, reviews reporting on treatment outcomes of these therapies are lacking. Methods A systematic literature review was conducted using Embase, MEDLINE, MEDLINE-In Process and Cochrane databases to identify the randomised/non-randomised controlled trials (RCTs/non-RCTs) and real-world observational studies of CAPS, HIDS/MKD and TRAPS published as full-texts (January 2000–September 2017) or conference abstracts (January 2014–September 2017). Studies with data for ≥1 biologic were included. Studies with <5 patients were excluded. Results Of the 3 342 retrieved publications, 72 studies were included (CAPS, n=43; HIDS/MKD, n=9; TRAPS, n=7; studies with ≥2 cohorts, n=13). Most studies were full-text (n=56), published after 2010 (n=56) and real-world observational studies (n=58). Among included studies, four were RCTs (canakinumab, n=2 (CAPS, n=1; HIDS/MKD and TRAPS, n=1); rilonacept, n=1 (in CAPS); simvastatin, n=1 (in HIDS/MKD)). Canakinumab and anakinra were the most commonly used therapies for CAPS and HIDS/MKD, whereas etanercept, canakinumab and anakinra were the most common for TRAPS. The available evidence suggested the efficacy or effectiveness of canakinumab and anakinra in CAPS, HIDS/MKD and TRAPS, and of etanercept in TRAPS; asingle RCT demonstrated the efficacy of rilonacept in CAPS. Conclusions Canakinumab, anakinra, etanercept and rilonacept were reported to be well tolerated; however, injection-site reactions were observed frequently with anakinra, rilonacept and etanercept. Data on the use of tocilizumab, infliximab and adalimumab in these conditions were limited; thus, further research is warranted." @default.
• W3045681719 created "2020-08-03" @default.
• W3045681719 creator A5001121977 @default.
• W3045681719 creator A5012501013 @default.
• W3045681719 creator A5051230084 @default.
• W3045681719 creator A5066582203 @default.
• W3045681719 creator A5073711042 @default.
• W3045681719 creator A5082997476 @default.
• W3045681719 date "2020-07-01" @default.
• W3045681719 modified "2023-10-15" @default.
• W3045681719 title "Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome" @default.
• W3045681719 cites W1138737324 @default.
• W3045681719 cites W1585104100 @default.
• W3045681719 cites W163117202 @default.
• W3045681719 cites W1781244235 @default.
• W3045681719 cites W189195583 @default.
• W3045681719 cites W1895520487 @default.
• W3045681719 cites W1950401339 @default.
• W3045681719 cites W1964034086 @default.
• W3045681719 cites W1968057560 @default.
• W3045681719 cites W1970294033 @default.
• W3045681719 cites W1970410801 @default.
• W3045681719 cites W1971133541 @default.
• W3045681719 cites W1973971414 @default.
• W3045681719 cites W1977884267 @default.
• W3045681719 cites W1985383819 @default.
• W3045681719 cites W1997486254 @default.
• W3045681719 cites W2005501262 @default.
• W3045681719 cites W2014067126 @default.
• W3045681719 cites W2024610145 @default.
• W3045681719 cites W2033023137 @default.
• W3045681719 cites W2036485405 @default.
• W3045681719 cites W2062143882 @default.
• W3045681719 cites W2062946728 @default.
• W3045681719 cites W2078659014 @default.
• W3045681719 cites W2096170290 @default.
• W3045681719 cites W2096467303 @default.
• W3045681719 cites W2098907544 @default.
• W3045681719 cites W2098923148 @default.
• W3045681719 cites W2099680271 @default.
• W3045681719 cites W2099808663 @default.
• W3045681719 cites W2100998301 @default.
• W3045681719 cites W2102497552 @default.
• W3045681719 cites W2109307284 @default.
• W3045681719 cites W2112875119 @default.
• W3045681719 cites W2114227513 @default.
• W3045681719 cites W2115022780 @default.
• W3045681719 cites W2115867185 @default.
• W3045681719 cites W2121837801 @default.
• W3045681719 cites W2121975203 @default.
• W3045681719 cites W2122536846 @default.
• W3045681719 cites W2125374122 @default.
• W3045681719 cites W2128762822 @default.
• W3045681719 cites W2129019356 @default.
• W3045681719 cites W2137991831 @default.
• W3045681719 cites W2144016275 @default.
• W3045681719 cites W2148501245 @default.
• W3045681719 cites W2149374693 @default.
• W3045681719 cites W2155274574 @default.
• W3045681719 cites W2156941953 @default.
• W3045681719 cites W2158249293 @default.
• W3045681719 cites W2161858472 @default.
• W3045681719 cites W2167172185 @default.
• W3045681719 cites W2286882807 @default.
• W3045681719 cites W2291204297 @default.
• W3045681719 cites W2292774566 @default.
• W3045681719 cites W2310667568 @default.
• W3045681719 cites W2323866919 @default.
• W3045681719 cites W2334778742 @default.
• W3045681719 cites W2340162653 @default.
• W3045681719 cites W2342393409 @default.
• W3045681719 cites W2345644935 @default.
• W3045681719 cites W2346472573 @default.
• W3045681719 cites W2407551672 @default.
• W3045681719 cites W2414265798 @default.
• W3045681719 cites W2473426512 @default.
• W3045681719 cites W2523463769 @default.
• W3045681719 cites W2527018141 @default.
• W3045681719 cites W2527759663 @default.
• W3045681719 cites W2552703312 @default.
• W3045681719 cites W2553520321 @default.
• W3045681719 cites W2554362738 @default.
• W3045681719 cites W2575445179 @default.
• W3045681719 cites W2587476825 @default.
• W3045681719 cites W2588463485 @default.
• W3045681719 cites W2588681363 @default.
• W3045681719 cites W2613072926 @default.
• W3045681719 cites W2624754514 @default.
• W3045681719 cites W2731378 @default.
• W3045681719 cites W2738956608 @default.
• W3045681719 cites W2755245455 @default.
• W3045681719 cites W2782966886 @default.
• W3045681719 cites W2804888720 @default.
• W3045681719 cites W2904275493 @default.
• W3045681719 cites W54362885 @default.
• W3045681719 doi "https://doi.org/10.1136/rmdopen-2020-001227" @default.
• W3045681719 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7722275" @default.
• W3045681719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32723831" @default.

• next